GammaMabs Pharma raised a round of funding on September 30, 2013.
GammaMabs Pharma is a biotechnology company developing a new monoclonal antibody targeting gynecological cancers, including ovarian cancer. Ovarian cancer is responsible for over 50 000 deaths every y…